fda semaglutide news 🎉Exciting that is now approved for MASH (aka fatty liver disease) “At week 72, the primary efficacy endpoint was based on histology (liver biopsy results). Interim results showed 63% FDA Warns on Certain Forms

High in casein protein, which can slow transit

PubMed Central, Diz-Chaves, Yolanda, et al

Managing Expectations: Timeline and Real-World Results Weight loss on semaglutide follows a predictable but individualized timeline: most patients see modest results in weeks 1-4 (1-3 lbs), accelerating between weeks 5-12 as their dose reaches therapeutic levels

Taken together, these data support a model where GLP1R is functional in advanced prostate cancer models and agonizing GLP1R in this context decreases glycolytic function

Lineage specific changes in the sequence and function have been described in hystricomorph rodents for the key metabolic gene insulin 31

Additionally, a persons diet and lifestyle choices play a crucial role